Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 21 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Early Phase 1

8(38.1%)

Phase 1

7(33.3%)

N/A

5(23.8%)

Phase 4

1(4.8%)

21Total

Early Phase 1(8)

Phase 1(7)

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT06809712Phase 1Recruiting

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT06709131Phase 1Suspended

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT06120166Early Phase 1Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Role: lead

NCT06902025Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia

Role: lead

NCT06887985Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

Role: lead

NCT06879470Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma

Role: lead

NCT06162338Not ApplicableRecruiting

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I

Role: lead

NCT06809699Phase 1Recruiting

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT04689204Early Phase 1Completed

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Role: lead

NCT06785519Early Phase 1Recruiting

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Role: lead

NCT05716113Early Phase 1Completed

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Role: lead

NCT06571825Phase 4Recruiting

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Role: lead

NCT06084962Phase 1Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Role: lead

NCT05444322Early Phase 1Unknown

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Role: lead

NCT05340829Phase 1Unknown

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

Role: lead

NCT04538599Phase 1Completed

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Role: lead

NCT04227015Early Phase 1Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Role: lead

NCT04626908Phase 1Unknown

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Role: lead

NCT04283006Early Phase 1Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Role: lead

NCT04448509Not ApplicableUnknown

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Role: lead